Oncolytic viruses (OVs)
- Using the promoter for expression of survivin, a highly cancer cell-specific protein, we have successfully developed a pipeline of OVs (the Surv.m-CRA series) that only attack cancer cells without attacking normal cells.
- In addition to Surv.m-CRA-1 currently in clinical development for the treatment of malignant bone tumors, we are also developing the Type 2 OV drug candidates “Surv.m-CRA-2-G” and “Surv.m-CRA-2-IC” armed with therapeutic genes that stimulate autoimmunity.
Viruses for in vivo gene therapy
- We have developed a pipeline of several therapeutic viruses armed with genes such as those encoding hepatocyte growth factor (HGF), which is effective in the treatment of hepatic disease and diabetes mellitus.
- We have confirmed the effects of these viral vectors in repairing liver damage and controlling blood glucose in nonclinical mouse models.